VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATMENT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL OF SYH2070 INJECTION FOR THE TREATME NT OF MIXED HYPERLIPIDAEMIA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that the Phase II clinical trial of SYH2070 Injection (the ‘‘Product ’’) developed by the Group for the treatment of mixed hyperlipidaemia has been officially initiated at the first centre in China. Existing therapeutic regimens for mixed hyperlipidaemia r equire the combined administration of multiple medicines. Currently, there remains an unmet clin ical need for treatments that can simultaneously reduce triglycerides ( ‘‘TG’’) and low-density lipoprotein cholesterol ( ‘‘LDL-C ’’). The Product is an N-acetylgalactosamine (GalNAc)-conjugated small interfering ribonucleic acid (siRNA) drug independently developed by the Group, targeting the an giopoietin-like 3 ( ‘‘ANGPTL3 ’’) messenger ribonucleic acid ( ‘‘mRNA ’’) in hepatocytes. The Product can persistently and specific ally silence ANGPTL3 mRNA and suppress the expression of ANGPTL3 protein, thereby enhancing lipoprotein lipase (LPL) activity and inhibiting endothel ial lipase (EL) activity. This reduces the conversion of very low-density lipoprotein (VLDL) to low-d ensity lipoprotein (LDL), achieving the goal of simultaneously, persistently, stably lowering TG a nd LDL-C, while significantly improving patient adherence through a longer dosing interval. – 1 – Previously, the Group obtained the Notice of Approval for Cl inical Trial of Drug (Acceptance No.: 2025LP02566) from the National Medical Products Administr ation of the People ’s Republic of China in September 2025, and has completed the Phase I clinical trial and initiated this Phase II clinical trial. This Phase II clinical trial is designed to evaluate the effi cacy, safety, pharmacokinetic (PK) profiles, and immunogenicity of the Product relative to placebo in sub jects with mixed hyperlipidaemia receiving lipid-lowering treatment, with a planned enrolm ent of 240 subjects. Currently, subject recruitment and screening are actively underway. By order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 7 July 2026 As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei , Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, M r. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors. – 2 –

The release as fetched from its publisher. irasia.com ↗